CD19 and BCMA-targeted allogeneic CAR-T cells
RN1201-Ab
Phase 1 gene_therapy active
Quick answer
CD19 and BCMA-targeted allogeneic CAR-T cells for Refractory Immune-mediated Platelet Transfusion Refractoriness is a Phase 1 program (gene_therapy) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Refractory Immune-mediated Platelet Transfusion Refractoriness
- Phase
- Phase 1
- Modality
- gene_therapy
- Status
- active